This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Villafranca, E. Articles by Brugarolas, A. Search for Related Content PubMed PubMed Citation Articles by Villafranca, E. Articles by Brugarolas, A.

Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer

From the Department of Oncology, Clínica Universitaria, University of Navarre, and Department of Oncology, Hospital of Navarre, Pamplona, Spain.

Address reprint requests to Elena Villafranca, MD, Department of Oncology, Clínica Universitaria de Navarra, Avda. Pío XII, 36, Pamplona, 31008, Spain; email: evillafran{at}unav.es

PURPOSE: Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. TS gene promoter possesses regulatory tandemly repeated (TR) sequences that are polymorphic in humans, depending on ethnic factors. These polymorphisms have been reported to influence TS expression. TS expression levels affect tumor downstaging after preoperative fluoruracil (5-FU)–based chemoradiation. Tumor downstaging correlates with improved local control and disease-free survival. The aim of this study is to correlate TR polymorphisms with downstaging and disease-free survival.

PATIENTS AND METHODS: Sixty-five patients with rectal cancer underwent tumor resection after preoperative 5-FU–based chemoradiation. Tumor downstaging was evaluated by comparing the pretreatment T stage with the pathologic stage observed in the surgical specimen. TS polymorphism genotype was determined by polymerase chain reaction amplification of the corresponding TS promoter region, and products of amplification were electrophoresed, obtaining products of 220 bp (2/2), 248 bp (3/3), or both (2/3). The TS polymorphism genotype results were subsequently compared with the downstaging observed and with disease-free survival.

RESULTS: Patients who were homozygous for triple TR (3/3) had a lower probability of downstaging than patients who were homozygous with double TR or heterozygous patients (2/2 and 2/3): 22% versus 60% (P = .036; logistic regression). Furthermore, a trend toward improved 3-year disease-free survival was detected in the 2/2 and 2/3 groups, compared with that in the 3/3 group (81% v 41%; P = .17).

CONCLUSION: This preliminary study suggests that TS repetitive-sequence polymorphisms are predictive for tumor downstaging. TR sequences in TS promoter may be useful as a novel means of predicting response to preoperative 5-FU–based chemoradiation.

This article has been cited by other articles:

				P. Bolufer, M. Collado, E. Barragan, J. Cervera, M.-J. Calasanz, D. Colomer, J. Roman-Gomez, and M. A. Sanz The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia Haematologica, March 1, 2007; 92(3): 308 - 314. [Abstract] [Full Text] [PDF]

				N. Han and S. Galandiuk Induction Chemoradiation for Rectal Cancer Arch Surg, December 1, 2006; 141(12): 1246 - 1252. [Abstract] [Full Text] [PDF]

				T. Liersch, C. Langer, B. M. Ghadimi, B. Kulle, D. E. Aust, G. B. Baretton, W. Schwabe, P. Hausler, H. Becker, and C. Jakob Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy J. Clin. Oncol., September 1, 2006; 24(25): 4062 - 4068. [Abstract] [Full Text] [PDF]

				X. Wu, J. Gu, T.-T. Wu, S. G. Swisher, Z. Liao, A. M. Correa, J. Liu, C. J. Etzel, C. I. Amos, M. Huang, et al. Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer J. Clin. Oncol., August 10, 2006; 24(23): 3789 - 3798. [Abstract] [Full Text] [PDF]

				W. Ichikawa, T. Takahashi, K. Suto, Y. Sasaki, and R. Hirayama Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen. Clin. Cancer Res., July 1, 2006; 12(13): 3928 - 3934. [Abstract] [Full Text] [PDF]

				S. Marsh and H. L. McLeod Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet., April 15, 2006; 15(suppl_1): R89 - R93. [Abstract] [Full Text] [PDF]

				E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al. Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment J. Clin. Oncol., April 1, 2006; 24(10): 1603 - 1611. [Abstract] [Full Text] [PDF]

				V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100. [Abstract] [Full Text] [PDF]

				V. Boeva, M. Regnier, D. Papatsenko, and V. Makeev Short fuzzy tandem repeats in genomic sequences, identification, and possible role in regulation of gene expression Bioinformatics, March 15, 2006; 22(6): 676 - 684. [Abstract] [Full Text] [PDF]

				R. A. Walgren, M. A. Meucci, and H. L. McLeod Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up? J. Clin. Oncol., October 10, 2005; 23(29): 7342 - 7349. [Abstract] [Full Text] [PDF]

				W. Tan, X. Miao, L. Wang, C. Yu, P. Xiong, G. Liang, T. Sun, Y. Zhou, X. Zhang, H. Li, et al. Significant increase in risk of gastroesophageal cancer is associated with interaction between promoter polymorphisms in thymidylate synthase and serum folate status Carcinogenesis, August 1, 2005; 26(8): 1430 - 1435. [Abstract] [Full Text] [PDF]

				J. C. C. Rocha, C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro, D. Campana, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia Blood, June 15, 2005; 105(12): 4752 - 4758. [Abstract] [Full Text] [PDF]

				M. A. Wright, G. Morrison, P. Lin, G. D. Leonard, D. Nguyen, X. Guo, E. Szabo, J. L. Hopkins, J. P. Leguizamo, N. Harold, et al. A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors Clin. Cancer Res., June 1, 2005; 11(11): 4144 - 4150. [Abstract] [Full Text] [PDF]

				S. Popat, R. Wort, and R. S. Houlston Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers International Journal of Surgical Pathology, April 1, 2005; 13(2): 127 - 133. [Abstract] [PDF]

				S. Popat, A. Matakidou, and R. S. Houlston In Reply: J. Clin. Oncol., March 20, 2005; 23(9): 2108 - 2109. [Full Text] [PDF]

				A. Jakobsen, J. N. Nielsen, N. Gyldenkerne, and J. Lindeberg Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil Sensitivity J. Clin. Oncol., March 1, 2005; 23(7): 1365 - 1369. [Abstract] [Full Text] [PDF]

				W. Lee, A. C. Lockhart, R. B. Kim, and M. L. Rothenberg Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development Oncologist, February 1, 2005; 10(2): 104 - 111. [Abstract] [Full Text] [PDF]

				J. Chen, C. Kyte, W. Chan, J. G. Wetmur, C. S. Fuchs, and E. Giovannucci Polymorphism in the Thymidylate Synthase Promoter Enhancer Region and Risk of Colorectal Adenomas Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2247 - 2250. [Abstract] [Full Text] [PDF]

				M. V. Relling, W. Yang, S. Das, E. H. Cook, G. L. Rosner, M. Neel, S. Howard, R. Ribeiro, J. T. Sandlund, C.-H. Pui, et al. Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia J. Clin. Oncol., October 1, 2004; 22(19): 3930 - 3936. [Abstract] [Full Text] [PDF]

				T. Lecomte, J.-M. Ferraz, F. Zinzindohoue, M.-A. Loriot, D.-A. Tregouet, B. Landi, A. Berger, P.-H. Cugnenc, R. Jian, P. Beaune, et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy Clin. Cancer Res., September 1, 2004; 10(17): 5880 - 5888. [Abstract] [Full Text] [PDF]

				R. Chan and D. J. Kerr Can we individualise chemotherapy for colorectal cancer? Ann. Onc., July 1, 2004; 15(7): 996 - 999. [Full Text] [PDF]

				L. Sharp and J. Little Polymorphisms in Genes Involved in Folate Metabolism and Colorectal Neoplasia: A HuGE Review Am. J. Epidemiol., March 1, 2004; 159(5): 423 - 443. [Abstract] [Full Text] [PDF]

				K. Uchida, K. Hayashi, K. Kawakami, S. Schneider, J. M. Yochim, H. Kuramochi, K. Takasaki, K. D. Danenberg, and P. V. Danenberg Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in the TS Gene Clin. Cancer Res., January 15, 2004; 10(2): 433 - 439. [Abstract] [Full Text] [PDF]

				J. Little, L. Sharp, S. Duthie, and S. Narayanan Colon Cancer and Genetic Variation in Folate Metabolism: The Clinical Bottom Line J. Nutr., November 1, 2003; 133(11): 3758S - 3766. [Abstract] [Full Text] [PDF]

				J. Chen, D. J. Hunter, M. J. Stampfer, C. Kyte, W. Chan, J. G. Wetmur, R. Mosig, J. Selhub, and J. Ma Polymorphism in the Thymidylate Synthase Promoter Enhancer Region Modifies the Risk and Survival of Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 958 - 962. [Abstract] [Full Text] [PDF]

				K. Kawakami and G. Watanabe Identification and Functional Analysis of Single Nucleotide Polymorphism in the Tandem Repeat Sequence of Thymidylate Synthase Gene Cancer Res., September 15, 2003; 63(18): 6004 - 6007. [Abstract] [Full Text] [PDF]

				Y. C. Hu, R. A. Komorowski, S. Graewin, G. Hostetter, O.-P. Kallioniemi, H. A. Pitt, and S. A. Ahrendt Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4165 - 4171. [Abstract] [Full Text] [PDF]

				T. Tsuji, S. Hidaka, T. Sawai, T. Nakagoe, H. Yano, M. Haseba, H. Komatsu, H. Shindou, H. Fukuoka, M. Yoshinaga, et al. Polymorphism in the Thymidylate Synthase Promoter Enhancer Region Is Not an Efficacious Marker for Tumor Sensitivity to 5-Fluorouracil-based Oral Adjuvant Chemotherapy in Colorectal Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3700 - 3704. [Abstract] [Full Text] [PDF]

				M. V. Mandola, J. Stoehlmacher, S. Muller-Weeks, G. Cesarone, M. C. Yu, H.-J. Lenz, and R. D. Ladner A Novel Single Nucleotide Polymorphism within the 5' Tandem Repeat Polymorphism of the Thymidylate Synthase Gene Abolishes USF-1 Binding and Alters Transcriptional Activity Cancer Res., June 1, 2003; 63(11): 2898 - 2904. [Abstract] [Full Text] [PDF]

				W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF]

				N J Maughan and P Quirke Pathology - a molecular prognostic approach: Advances in colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 59 - 74. [Abstract] [Full Text] [PDF]

				M. Derenzini, L. Montanaro, A. Chilla, E. Tosti, C. Ceccarelli, F. Dall'Olio, D. Ofner, and D. Trere Evaluation of Thymidylate Synthase Protein Expression by Western Blotting and Immunohistochemistry on Human Colon Carcinoma Xenografts in Nude Mice J. Histochem. Cytochem., December 1, 2002; 50(12): 1633 - 1640. [Abstract] [Full Text] [PDF]

				H. L. McLeod Genetic Strategies to Individualize Supportive Care J. Clin. Oncol., June 15, 2002; 20(12): 2765 - 2767. [Full Text] [PDF]

				M.-C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, J.-L. Formento, M. Francoual, P. Formento, N. Renee, E. Chamorey, et al. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses J. Clin. Oncol., June 15, 2002; 20(12): 2832 - 2843. [Abstract] [Full Text] [PDF]

				J. S. Macdonald Vive La Difference: Sex and Fluorouracil Toxicity J. Clin. Oncol., March 15, 2002; 20(6): 1439 - 1441. [Full Text] [PDF]

				K. Kawakami, D. Salonga, J. M. Park, K. D. Danenberg, H. Uetake, J. Brabender, K. Omura, G. Watanabe, and P. V. Danenberg Different Lengths of a Polymorphic Repeat Sequence in the Thymidylate Synthase Gene Affect Translational Efficiency but Not Its Gene Expression Clin. Cancer Res., December 1, 2001; 7(12): 4096 - 4101. [Abstract] [Full Text] [PDF]

				F. Zinzindohoue, J.-M. Ferraz, and P. Laurent-Puig Thymidylate Synthase Promoter Polymorphism J. Clin. Oncol., July 15, 2001; 19(14): 3442 - 3442. [Full Text]